首页> 美国卫生研究院文献>Stem Cells International >Human Amnion Epithelial Cell Therapy for Chronic Liver Disease
【2h】

Human Amnion Epithelial Cell Therapy for Chronic Liver Disease

机译:人羊膜上皮细胞疗法治疗慢性肝病

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Liver fibrosis is a common consequence of chronic liver disease. Over time, liver fibrosis can develop into liver cirrhosis. Current therapies for liver fibrosis are limited, and liver transplant is the only curative therapy for patients who progress to end-stage disease. A potential approach to treat chronic liver disease with increasing interest is cell-based therapy. Among the multiple cell types which have been proposed for therapeutic uses, human amnion epithelial cells and amniotic fluid-derived mesenchymal cells are promising. These cells are highly abundant, and their use poses no ethical concern. Furthermore, they exert potent anti-inflammatory and antifibrotic effects in animal models of liver injury. This review highlights the therapeutic characteristics and discusses how human amnion epithelial cells can be utilised as a therapeutic tool for chronic liver disease.
机译:肝纤维化是慢性肝病的常见后果。随着时间的流逝,肝纤维化可发展为肝硬化。当前用于肝纤维化的疗法是有限的,并且肝移植是进展为末期疾病的患者的唯一治愈性疗法。一种越来越引起人们关注的治疗慢性肝病的潜在方法是基于细胞的疗法。在已提出用于治疗用途的多种细胞类型中,人羊膜上皮细胞和羊水来源的间充质细胞是有希望的。这些细胞非常丰富,其使用没有任何道德上的考虑。此外,它们在肝损伤的动物模型中发挥有效的抗炎和抗纤维化作用。这篇综述突出了治疗特性,并讨论了如何将人羊膜上皮细胞用作慢性肝病的治疗工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号